



July 29, 2021

Santen to Present Latest Data including STN1012700 (DE-127) and STN1007603 (DE-076C)
at 33rd APACRS 2021 meeting

Santen Pharmaceutical Co., Ltd. (Head Office in Osaka, hereinafter “Santen”) announced today that some publications related to STN1012700 (DE-127), a non-selective muscarinic antagonist, STN1007603 (DE-076C), an ophthalmic emulsion which has immunosuppressive effect, etc. will be presented at the virtual Asia-Pacific Association of Cataract and Refractive Surgeons (33rd APACRS; <http://apacrs-snec2021.org/>) meeting from July 30 to 31, 2021.

STN1007603 has been launched as *Verkazia* for the treatment of vernal keratoconjunctivitis in several countries including Europe and Asia. *Verkazia* was also recently approved in U.S. in June 2021 and a marketing approval has been submitted in China in April 2021. Santen has also been conducting a Phase 2/3 study to investigate STN1012700 (DE-127) for slowing myopia progression in children in Japan and plans to initiate a Phase 1 study in China in FY2021.

The recent Phase 2 study data of STN10127 from APPLE study in Asia and pooled safety data of *Verkazia* from NOVATIVE/VEKTIS Phase 3 studies, that were included in the U.S. label will be presented at APACRS meeting this year.

Presentation topics

Poster ID	Title
PP5-66	Efficacy and Safety of DE-127 versus Placebo in Mild or Moderate Myopia: The APPLE study
PP5-67	Changes in Axial Length of DE-127 (0.0025%, 0.005%, 0.01%) versus Placebo for Slowing Myopia Progression: The APPLE study
PP5-15	Safety/Tolerability of Topical Cyclosporine A Cationic Emulsion in Pediatric Patients with Active Severe VKC: Pooled NOVATIVE/VEKTIS trial results
PP5-97	Safety Outcomes of Microshunt Implantation vs. Trabeculectomy in Patients with Primary Open-angle Glaucoma

In addition, Glaukos Corporation (San Clemente, CA, U.S.) is responsible for developing and selling products in the Americas, Australia, and New Zealand (press release on May 19, 2021; <https://www.santen.com/en/news/20210519-1.pdf>).

Contact:

Investor Relations Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.com